The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

A new study highlights a significant medical concern for individuals suffering from psoriasis, revealing that even when skin ...

A new study reveals psoriasis may increase the risk of obesity and fatty liver despite skin improvements Learn why managing ...

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

In a country where chronic skin diseases affect millions, one institution is rewriting the rulebook. Kayakalp Global, based ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

Learn to distinguish between nail psoriasis and nail fungus through key visual differences, associated symptoms, and ...

Skin symptoms may clear with biologics in psoriasis, but hidden internal inflammation often persists, contributing to major ...

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

Residual inflammation persisted among patients with psoriasis despite optimal disease response to biologic therapies, putting ...